Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1

Biochemical and Biophysical Research Communications

Volumn 408, Issue 4, 2011, Pages 692-696

  Veggiani, Gianluca ^a   Ossolengo, Giuseppe ^a   Aliprandi, Marisa ^a   Cavallaro, Ugo ^a   de Marco, Ario ^a,b  

^a FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^b UNIVERSITY OF NOVA GORICA   (Slovenia)

Author keywords

Competitive elution; Fibroblast growth factor receptor 1; Llama VHH; MCF7 cells; Receptor internalization; Single domain antibodies

Indexed keywords

EPITOPE; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HEPARIN; RECOMBINANT ANTIBODY; RECOMBINANT ANTIBODY VHH; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BIOPANNING; CONTROLLED STUDY; ELUTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTERNALIZATION; PHAGE DISPLAY; PRIORITY JOURNAL;

ANTIBODIES; CELL NUCLEUS; FIBROBLAST GROWTH FACTORS; HELA CELLS; HUMANS; LIGANDS; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1;

LAMA (MAMMAL);

EID: 79956188243     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.090     Document Type: Article

References (30)

1. Hughes S.E. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J. Histochem. Cytochem. 1997, 45:1005-1019.
2. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
3. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5:1063-1071.
4. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M., Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60:7163-7169.
5. Koziczak M., Holbro T., Hynes N.E. Blocking of FGFR signaling inhibits breast cancer proliferation through downregulation of D-type cyclins. Oncogene 2004, 23:3501-3508.
6. Francavilla C., Cattaneo P., Berezin V., Bock E., Ami D., de Marco A., Christofori G., Cavallaro U. The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking. J. Cell Biol. 2009, 187:1101-1116.
7. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.
8. Rapraeger A.C., Krufka A., Olwin B.B. Requirement of heparin sulfate for FGF-2-mediated fibroblast growth and myoblast differentiation. Science 1991, 252:1705-1708.
9. Uematsu F., Kan M., Wang F., Jang J.H., Luo Y., McKeehan W.L. Ligand binding properties of binary complexes of heparin and immunoglobulin-like modules of FGF receptor 2. Biochem. Biophys. Res. Commun. 2000, 272:830-836.
10. Maher P.A. Nuclear translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J. Cell Biol. 1996, 134:529-536.
11. Lin S.Y., Makino K., Xia W.M., Matin A., Wen Y., Kwong L K.Y., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell. Biol. 2001, 3:802-808.
12. Monegal A., Ami D., Martinelli C., Huang H., Aliprandi M., Capasso P., Francavilla C., Ossolengo G., de Marco A. Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. Prot. Eng. Des. Sel. 2009, 22:273-280.
13. Bryant D.M., Wylie F.G., Stow J.L. Regulation of endocytosis, nuclear translocation, and signaling of Fibroblast Growth Factor Receptor 1 by E-Cadherin. Mol. Biol. Cell 2005, 16:14-23.
14. M. Aliprandi, E. Sparacio, F. Pivetta, G. Ossolengo, R. Maestro, A. de Marco, The availability of a recombinant anti-SNAP antibody in VHH format amplifies the application flexibility of SNAP-tagged proteins, J. Biomed. Biotech. (2010) ID: 658954.
15. Morris G.E. Epitope mapping of protein antigens by competition ELISA. The Protein Protocols Handbook 1996, 595-600. Humana Press, Inc., Totowa, NJ. J.M. Walker (Ed.).
16. Tvorogov D., Anisimov A., Zheng W., Leppänen V.-M., Tammela T., Laurinavicius S., et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640.
17. Chames P., Van Regenmortel M., Weiss E., Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157:220-233.
18. Emde A., Pradeep C.-R., Ferraro D.A., Ben-Chetrit N., Sela M., Ribba B., et al. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 2011, 30:1631-1642.
19. Bradbury A.R.M., Sidhu S., Dübel S., McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 2011, 29:245-254.
20. Olichon A., Schweizer D., Muyldermans S., de Marco A. Heating represents a rapid purification method for recovering correctly folded thermo tolerant VH and VHH domains. BMC Biotechnol. 2007, 7:7.
21. Dolk E., van der Vaart M., Hulsik D.L., Vriend G., de Haard H.J., Spinelli S., et al. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl. Environ. Microbiol. 2005, 71:442-450.
22. Doňa V., Urrutia M., Bayardo M., Alzogaray V., Goldbaum F.A., Chirdo F.G. Single domain antibodies are specially suited for quantitative determination of gliadins under denaturing conditions. J. Agric. Food Chem. 2010, 58:918-926.
23. Jähnichen S., Blanchetot C., Maussang D., Gonzalez-Pajuelo M., Chow K.Y., Bosch L., et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. USA 2010, 107:20565-20570.
24. Forsman A., Beirnaert E., Aasa-Chapman M.M.I., Hoorelbeke B., Hijazi K., Koh W., et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 2008, 82:12069-12081.
25. Kabir M.E., Krishnaswamy S., Miyamoto M., Furuichi Y., Komiyama T. An improved phage-display panning method to produce an HM-1 killer toxin anti-idiotypic antibody. BMC Biotechnol. 2009, 9:99.
26. Ronca R., Benzoni P., Leali D., Urbinati C., Belleri M., Corsini M., et al. Anti-angiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol. Cancer Ther. 2010, 9:3244-3253.
27. Reilly J.F., Maher P.A. Importin β-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J. Cell Biol. 2001, 152:1307-1312.
28. G. Veggiani, A. de Marco, Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase, Prot. Expr. Purif., in press, doi:10.1016/j.pep.2011.03.005.
29. Nguyen V.D., Hatahet F., Salo K.E., Enlund E., Zhang C., Ruddock L.W. Pre-expression of sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E. coli. Microb. Cell Fact. 2011, 10:1-13.
30. Turner N., Grose R. Fibroblast growth factor signaling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.